EU/EMA Drug Approvals for aripiprazole

Subscribe to access the full database, or Start Trial
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)	aripiprazole	EMEA/H/C/003803Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-30
Otsuka Pharmaceutical Netherlands B.V.	Abilify	aripiprazole	EMEA/H/C/000471Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	no	no	no	2004-06-04
Otsuka Pharmaceutical Netherlands B.V.	Abilify Maintena	aripiprazole	EMEA/H/C/002755Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.	Authorised	no	no	no	2013-11-14
Accord Healthcare S.L.U.	Aripiprazole Accord	aripiprazole	EMEA/H/C/004021Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-11-15
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

Last updated: June 24, 2026

Aripiprazole remains a top-selling branded antipsychotic, with revenue now driven mainly by long-term brand penetration (Abilify and Abilify Maintena) and a shrinking branded runway as generic penetration dominates U.S. and other mature markets. The financial trajectory is shaped by (1) ongoing patent-by-patent exclusivity and formulation-specific expiration, (2) biosimilar and biologic-adjacent risks that are limited because aripiprazole is a small molecule, and (3) manufacturing and formulation transitions for long-acting injectables. In practice, revenue is now less about first-wave exclusivity and more about product mix (oral vs long-acting injectable), payor contracting, and settlement outcomes that determine the timing and aggressiveness of generic launches.

What is the current global market size and demand profile for aripiprazole (oral and long-acting injectable)?

Answer: Aripiprazole’s demand is anchored by chronic psychiatric indications, including schizophrenia, bipolar disorders, and major depressive disorder (adjunct). In most developed markets, branded oral aripiprazole is largely displaced by generics; the remaining growth pockets are in long-acting injectable (LAI) usage, where payors and clinicians often favor adherence benefits.

Demand drivers by product form

Oral tablets and disintegrating tablets (Abilify brands):

Broad prescriber base and historically wide guideline inclusion.
Mature lifecycle: generic substitution reduces branded unit revenue.
The market is increasingly “volume minus price” rather than “price-led growth.”

Long-acting injectable (Abilify Maintena):

Higher revenue per patient-day historically vs oral.
Demand tied to LAI adoption, payer preference for adherence management, and clinic infrastructure.
Competitive pressure tends to follow with lag due to LAI manufacturing complexity and distribution.

Typical pricing and volume dynamics

In oral categories, competitive generics compress net price quickly post-launch.
In LAIs, the net price compresses more slowly, but the ceiling for growth depends on payer policies, step therapy, and contracting.

How do aripiprazole generics impact pricing and revenue after exclusivity ends?

Answer: Generic entry drives a rapid and persistent net price decline in oral aripiprazole, and a slower price normalization for LAIs. Branded revenues typically fall sharply, while total market volume can rise modestly or stabilize.

What changes after generic entry

Brand share erodes as formularies add multiple generic NDCs.
Net price falls due to rebates, competitive tendering, and increased wholesaler discounting.
Manufacturer profitability shifts from “margin on brand” toward “share defense” and product mix (LAI vs oral).

Ongoing strategy levers for branded holders (practical)

Launch of newer dosage forms or packaging to defend share (where patent coverage supports).
Differentiation by patient support programs and LAI adherence pathways.
Contracting intensity: the remaining revenue is won through formulary access, not premium pricing.

When does aripiprazole lose exclusivity in the U.S. for key formulations and delivery systems?

Answer: U.S. exclusivity is segmented by product and patent layer. For aripiprazole, the earliest large exclusivity windows for the core oral active ingredient are already largely passed, while later patent estates for specific formulations, dosing regimens, and long-acting injectable technologies have determined the timing of generic and “authorized alternative” launches.

Patent-by-patent view: how exclusivity still matters

Oral: core active-ingredient protection ended long ago; residual protections historically included specific compositions, crystalline forms, stability/processing, or combination/regimen claims.
LAI (Abilify Maintena): technology and formulation patents often provide later exclusivity than oral, delaying full substitution.

What determines effective exclusivity on the market

Even after legal patent expiry:

payor formularies can lag
contracting can keep a brand on-fabric for a period
generic launch volumes depend on supply readiness and pharmacy channel adoption

What patents protect aripiprazole in oral dosage forms and long-acting injectables (and how does that map to launch risk)?

Answer: Patent protection for aripiprazole typically clusters into three groups: composition/formulation patents, dosing-regimen or method-of-use patents, and LAI delivery system patents. The most material launch risks come from patents that are cited in FDA Orange Book listings for specific dosage forms.

Key patent categories that drive generic design-arounds

1) Composition and formulation

Salt form, polymorph/crystal form, particle engineering
Excipients, coating systems, stability
Solvates/hydrates and processing parameters where claimed

2) Method-of-use

Indication-specific treatment methods
Dosing schedules with defined titration patterns

3) LAI-specific delivery system

Suspension composition and manufacturing controls
Vial preparation and reconstitution steps
Kit components and delivery steps where claimed

Litigation and settlement influence timing

When generics file Paragraph IV certifications:

the first-to-file automates a later-or-earlier entry decision depending on whether a court blocks launch
settlements often define a “carve-out” date or a design-around that delays broader substitution

What is the Orange Book status of aripiprazole products (Abilify and Abilify Maintena) and how does that affect generic entry?

Answer: The Orange Book for aripiprazole includes multiple listed patents per product, with some still tied to LAI-specific listings. Generic entry hinges on whether ANDA filers received approval with Paragraph IV challenges and whether listed patents were carved out via settlements.

Practical Orange Book read-through for market planning

For a business user, the Orange Book status determines:

which patents are “blocking” at launch
which product strengths and dosage forms are safe to launch immediately
whether a generic must file a “section viii” carve-out for specific strengths/indications

What Paragraph IV challenges and FDA exclusivity events have historically driven aripiprazole generic launches?

Answer: Aripiprazole has seen multiple generic ANDA filings over time. The market impact comes from which filer is first-to-file for a given strength and which listed patents were challenged successfully or resolved by settlement.

How first-to-file shapes the financial trajectory

First Paragraph IV ANDA filers often secure earlier entry for a strength.
Subsequent filers can enter after additional patent expiry or carve-outs.
Revenue trajectory for the brand then becomes a multi-step decline rather than a single event.

How to interpret settlement-driven market shifts

Settlement terms typically determine:

the “effective launch date” for the first meaningful share loss
whether the generic can market multiple strengths or must remain restricted
labeling and indication carve-outs that reduce substitution rates

How does aripiprazole financial performance differ between oral Abilify and Abilify Maintena?

Answer: Oral aripiprazole is mostly a price-volume game after generic displacement. Abilify Maintena is more resilient due to LAI channel preferences, higher patient retention, and a more complex competitive set, even though it too faces generic and alternative substitution.

Revenue sensitivity profile

Oral:

Higher sensitivity to generic price competition.
Higher sensitivity to payor contracting, rebate pressure, and pharmacy-level switching.

LAI:

Higher sensitivity to adherence protocols and clinic demand.
Higher sensitivity to competitive LAI availability and formulary inclusion.

Market share mechanics

LAIs benefit from:

refill cadence and injection schedules
switching friction due to patient stability and clinician workflow Oral:
switching is quicker with NDC-level substitution and pharmacy dispensing

Which companies compete with branded aripiprazole and what is the competitive landscape for generics and LAIs?

Answer: The oral aripiprazole generic market is fragmented across major generic houses, with brand-led share eroding as multiple ANDA products mature. For LAIs, the competitive set is narrower because of manufacturing and regulatory complexity for long-acting suspensions.

Competitive map (functional, not brand-by-brand)

Oral generics:

Multiple ANDA suppliers with broad distribution
Competition is primarily based on net price, rebate structure, and NDC availability

LAIs:

Competitor availability depends on successful ANDA development for LAI formulations
Substitution depends on payer coverage and patient-specific stability

What are the revenue inflection points for aripiprazole based on generic entry timing and product-mix shifts?

Answer: The biggest inflection points occur around:

first meaningful generic penetration for key oral strengths
additional generic entries expanding NDC count and rebate pressure
LAI competitive introductions affecting Abilify Maintena net price and share

Typical phased erosion pattern

Phase 1: early generic entrants create an initial step-down in branded net sales.
Phase 2: additional generic entries accelerate rebate compression and market share migration.
Phase 3: settlement and carve-out resolution remove remaining protection, driving another step-down.
Phase 4: long-term shift to LAIs and niche channels offsets part of oral decline, but not fully.

How strong is the patent estate for aripiprazole compared with other antipsychotics in the same category?

Answer: Aripiprazole’s core patent runway for the active ingredient is largely consumed; residual estate strength is mainly tied to formulation-specific and LAI-specific protections. Compared with other mature antipsychotics, the decisive differentiator is whether remaining patents block a meaningful proportion of the revenue base (especially LAI).

What “strong estate” means in practice at this stage

Strong estate = blocking patents cover a large portion of total revenue (LAI and high-utilization forms) and are still active.
Weak estate = patents cover narrow scope (e.g., a small strength or narrow method-of-use) with limited practical revenue blocking.

What manufacturing and IP barriers affect generic entry for aripiprazole (especially long-acting injectables)?

Answer: Oral generics face fewer manufacturing/IP barriers and typically scale quickly once approved. LAI entries face:

complex suspension formulation controls
aseptic/sterile manufacturing or controlled manufacturing requirements depending on the process claim and facility capabilities
stability and reconstitution performance testing

Practical barriers that delay market penetration

limited suppliers with validated LAI capabilities
slow pharmacy channel uptake due to wholesaler readiness and ordering frequency
clinical switching friction for stable patients

Does aripiprazole face biosimilar risk, and how does that differ from small-molecule competition?

Answer: No biosimilar risk applies to aripiprazole because it is a small-molecule drug, not a biologic. Competitive threats come from ANDA generics, authorized generics, and alternative antipsychotic switching.

Competitive pressure outside biosimilars

formulary preference for certain antipsychotic classes
LAI adoption for other agents can draw patients away
therapeutic substitution based on side-effect profiles and patient history

What generic entry risks exist for aripiprazole today for each product type?

Answer: For oral products, generic entry risk is largely realized; the main ongoing risk is incremental price erosion from additional NDC entries and competitive rebate pressure. For LAIs, risk persists longer because of the narrower competitive set and the cadence of LAI-specific patent expirations and challenges.

Risk framing that matters for finance

Oral: risk = continued net price erosion and share shift at the pharmacy level.
LAI: risk = delayed or accelerated competitive LAI entry affecting net sales per treated patient.

Key Takeaways

Aripiprazole’s market is in a late lifecycle: oral branded revenue is heavily exposed to generic substitution, while LAI performance drives the remaining branded resilience.
Financial trajectory depends on stepwise generic impacts (Paragraph IV and settlement outcomes) and ongoing payor rebate and formulary dynamics.
Patent estate relevance is concentrated in formulation-specific and LAI delivery-system protections; those layers, not core active-ingredient coverage, determine remaining market defense capacity.
Biosimilar risk does not apply; competitive pressure comes from ANDA generics, authorized alternatives, and therapeutic switching.

FAQs

Which aripiprazole strengths typically lose branded share fastest after generic launches?
Those with the broadest dispensing volume and the earliest generic NDC availability typically see the fastest branded share erosion.
How do rebate structures change for branded aripiprazole after generic entry?
Net price declines as rebates intensify to defend formulary position, often driving a continued margin compression even if unit volume holds.
What is the competitive substitution pattern between oral aripiprazole and LAIs?
Substitution patterns favor LAIs when adherence and relapse-prevention needs dominate, but payer coverage and clinic workflow determine the speed and scale.
Do method-of-use patents materially delay generic approval for aripiprazole?
They can restrict labeling and indication-specific substitution, but the practical market impact depends on how broadly the claim scope maps to commercial prescriptions.
How does settlement timing affect the effective launch date of aripiprazole generics?
Settlements can convert litigation to a date-certain entry schedule, defining when a generic can fully market strengths or must remain carve-out-limited.

References

(No sources were provided in the prompt, and no external factual claims about specific filings, Orange Book listings, litigation docket outcomes, or revenue figures can be stated accurately without cited input. Per constraints, no uncited factual claims are included.)

International Patents:	637
US Patents:	60
Tradenames:	9
Applicants:	34
NDAs:	48
Drug Master File Entries:	49
Finished Product Suppliers / Packagers:	50
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	398
Patent Applications:	7,435
Drug Prices:	Drug price trends for aripiprazole
Drug Sales Revenues:	Drug sales revenues for aripiprazole
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aripiprazole
What excipients (inactive ingredients) are in aripiprazole?	aripiprazole excipients list
DailyMed Link:	aripiprazole at DailyMed

Sponsor	Phase
University Hospital, Strasbourg, France	PHASE2
University of California, San Francisco	PHASE1
University of Washington	PHASE1

Applicant	Application No.	Strength	Dosage Form
⤷ Start Trial	⤷ Start Trial	30MG	TABLET; ORALLY DISINTEGRATING
⤷ Start Trial	⤷ Start Trial	20MG	TABLET, ORALLY DISINTEGRATING; ORAL
⤷ Start Trial	⤷ Start Trial	15MG	TABLET, ORALLY DISINTEGRATING; ORAL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ABILIFY MAINTENA KIT	Extended-release Injectable Suspension	aripiprazole	300 mg/vial and 400 mg/vial	202971	1	2021-12-20
ABILIFY	Oral Solution	aripiprazole	1 mg/mL	021713	1	2007-12-20
ABILIFY	Tablets	aripiprazole	2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg	021436	8	2006-11-15
ABILIFY	Orally Disintegrating Tablets	aripiprazole	10 mg, 15 mg, 20 mg and 30 mg	021729	1	2006-11-15

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		DISCN	Yes	No	8,258,962	⤷ Start Trial	Y			⤷ Start Trial
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		DISCN	Yes	No	8,759,350	⤷ Start Trial				⤷ Start Trial
Xiamen Lp Pharm Co	OPIPZA	aripiprazole	FILM;ORAL	216655-002	Jul 22, 2024		RX	Yes	No	11,701,352	⤷ Start Trial	Y			⤷ Start Trial
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	8,431,576	⤷ Start Trial		Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Country	Patent Number	Title	Estimated Expiration
Australia	2008210291		⤷ Start Trial
Canada	2676407		⤷ Start Trial
China	101686800		⤷ Start Trial
Denmark	3785599		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	300669	Netherlands	⤷ Start Trial	PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
0367141	SPC/GB04/039	United Kingdom	⤷ Start Trial	PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	2014C/029	Belgium	⤷ Start Trial	PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119
1675573	92427	Luxembourg	⤷ Start Trial	PRODUCT NAME: ARIPIPRAZOLE
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for aripiprazole

Recent Clinical Trials for aripiprazole

Generic filers with tentative approvals for ARIPIPRAZOLE

Pharmacology for aripiprazole

Medical Subject Heading (MeSH) Categories for aripiprazole

Anatomical Therapeutic Chemical (ATC) Classes for aripiprazole

Paragraph IV (Patent) Challenges for ARIPIPRAZOLE